Cardiovascular Disease Risk Factors Profile in Individuals With Diabetes Compared With Non-Diabetic Subjects in North-East of Iran

Authors Information
Article Notes and Dates
To Cite : Niroumand S, Dadgarmoghaddam M, Eghbali B, Abrishami M, Gholoobi A, et al. Cardiovascular Disease Risk Factors Profile in Individuals With Diabetes Compared With Non-Diabetic Subjects in North-East of Iran, Iran Red Crescent Med J. 2016 ;18(8):e29382. doi: 10.5812/ircmj.29382.
Copyright: Copyright © 2016, Iranian Red Crescent Medical Journal. .
Abstract
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Taylor KS, Heneghan CJ, Farmer AJ, Fuller AM, Adler AI, Aronson JK, et al. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013; 36(8): 2366-71[DOI][PubMed]
  • 2. Cigolle CT, Blaum CS, Halter JB. Diabetes and cardiovascular disease prevention in older adults. Clin Geriatr Med. 2009; 25(4): 607-41[DOI][PubMed]
  • 3. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012; 35(12): 2650-64[DOI][PubMed]
  • 4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5): 1047-53[PubMed]
  • 5. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87(1): 4-14[DOI][PubMed]
  • 6. Khajedaluee M, Dadgarmoghaddam M, Saeedi R, Izadi-Mood Z, Abrishami M. The Burden of Diabetes in a Developing Country. Open J Prevent Med. 2014; 4(4): 175-81[DOI]
  • 7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258): 405-12[PubMed]
  • 8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837-53[PubMed]
  • 9. Farmer JA. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diab Rep. 2008; 8(1): 71-7[PubMed]
  • 10. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291(3): 335-42[DOI][PubMed]
  • 11. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29(8): 1963-72[DOI][PubMed]
  • 12. Dadgarmoghaddam M, Khajedaluee M, Khadem-Rezaiyan M, Niroumand S, Abrishami M, Joya M, et al. Risk Factors for Non-communicable Disease: A Population Based Study in Mashhad (Iran). Br J Med Med Res. 2015; 7(6): 503-11[DOI]
  • 13. Mean Body Mass Index. 2014;
  • 14. World Health Organization. Obesity: Prevention and Managing the Global Epidemic. WHO Obesity Technical Reports Series 894.
  • 15. American Diabetes A. Standards of medical care in diabetes--2013. Diabetes Care. 2013; 36 Suppl 1-66[DOI][PubMed]
  • 16. Haffner SM, American Diabetes A. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004; 27 Suppl 1-71[PubMed]
  • 17. Rakesh MP, Joshi SR, Menon PS, Shah NS. Prevalence and pattern of diabetic dyslipidemia in Indian type 2 diabetic patients. Diabetes Metabol Syndrome Clin Res Rev. 2010; 4(1): 10-2[DOI]
  • 18. Jayarama N, Reddy M, Lakshmaiah V. Prevalence and pattern of dyslipidemia in type 2 diabetes mellitus patients in a rural tertiary care centre, southern India. Glob J Med Public Health. 2012; 1: 24-8
  • 19. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985; 110(5): 1100-7[PubMed]
  • 20. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997; 20(11): 1683-7[PubMed]
  • 21. Dehghan A, van Hoek M, Sijbrands EJ, Stijnen T, Hofman A, Witteman JC. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care. 2007; 30(10): 2695-9[DOI][PubMed]
  • 22. Haffner SM. Epidemiology of Type 2 Diabetes: Risk Factors. Diabetes Care. 1998; 21-6[DOI]
  • 23. Hachem SB, Mooradian AD. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs. 2006; 66(15): 1949-69[PubMed]
  • 24. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003; 46(6): 733-49[DOI][PubMed]
  • 25. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin North Am. 2004; 88(4): 897-909[DOI][PubMed]
  • 26. Del Pilar Solano M, Goldberg RB. Management of diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2005; 34(1): 1-25[DOI][PubMed]
  • 27. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2006; 35(3): 491-510[DOI][PubMed]
  • 28. Janghorbani M, Amini M. Metabolic syndrome in type 2 diabetes mellitus in isfahan, iran: prevalence and risk factors. Metab Syndr Relat Disord. 2007; 5(3): 243-54[DOI][PubMed]
  • 29. World Health Statistics 2012. 2013;
  • 30. Al-Adsani A, Memon A, Suresh A. Pattern and determinants of dyslipidaemia in type 2 diabetes mellitus patients in Kuwait. Acta Diabetol. 2004; 41(3): 129-35[PubMed]
  • 31. Ahmed N, Khan J, Siddiqui TS. Frequency of dyslipidaemia in type 2 diabetes mellitus in patients of Hazara division. J Ayub Med Coll Abbottabad. 2008; 20(2): 51-4[PubMed]
  • 32. Sert M, Morgul G, Tetiker BT. Diabetic dyslipidemia is a well-known issue, but what about lipoprotein a levels in Type 2 diabetics. Int J Diabetes Metabol. 2010; 18: 81-7
  • 33. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 444(7121): 881-7[DOI][PubMed]
  • 34. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444(7121): 840-6[DOI][PubMed]
  • 35. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006; 444(7121): 847-53[DOI][PubMed]
  • 36. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5)-41[DOI][PubMed]
  • 37. Sajjadi F, Mohammadifard N, Kelishadi R, Ghaderian N, Alikhasi H, Maghrun M. Clustering of coronary artery disease risk factors in patients with type 2 diabetes and impaired glucose tolerance. East Mediterr Health J. 2008; 14(5): 1080-9[PubMed]
  • 38. Harati H, Hadaegh F, Saadat N, Azizi F. Population-based incidence of Type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran. BMC Public Health. 2009; 9: 186[DOI][PubMed]
  • 39. Hadaegh F, Zabetian A, Harati H, Azizi F. The prospective association of general and central obesity variables with incident type 2 diabetes in adults, Tehran lipid and glucose study. Diabetes Res Clin Pract. 2007; 76(3): 449-54[DOI][PubMed]
  • 40. Hosseinpanah F, Rambod M, Azizi F. Population attributable risk for diabetes associated with excess weight in Tehranian adults: a population-based cohort study. BMC Public Health. 2007; 7: 328[DOI][PubMed]
  • 41. Li M, Fisette A, Zhao XY, Deng JY, Mi J, Cianflone K. Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. Int J Obes (Lond). 2009; 33(4): 424-39[DOI][PubMed]
  • 42. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008; 93(11 Suppl 1)-63[DOI][PubMed]
  • 43. Palaniappan LP, Kwan AC, Abbasi F, Lamendola C, McLaughlin TL, Reaven GM. Lipoprotein abnormalities are associated with insulin resistance in South Asian Indian women. Metabolism. 2007; 56(7): 899-904[DOI][PubMed]
  • 44. Shabnam AA, Homa K, Reza MT, Bagher L, Hossein FM, Hamidreza A. Cut-off points of waist circumference and body mass index for detecting diabetes, hypercholesterolemia and hypertension according to National Non-Communicable Disease Risk Factors Surveillance in Iran. Arch Med Sci. 2012; 8(4): 614-21[DOI][PubMed]
  • 45. Sarrafzadegan N, Kelishadi R, Najafian A, Khosravi A, Bahonar A, Asgary S, et al. Anthropometric indices in association with cardiometabolic risk factors: findings of the Isfahan Healthy Heart Program. ARYA Atheroscler. 2010; 5(4)
  • 46. Heshmat R, Khashayar P, Meybodi HR, Homami MR, Larijani B. The appropriate waist circumference cut-off for Iranian population. Acta Med Indones. 2010; 42(4): 209-15[PubMed]
  • 47. Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. Arch Iran Med. 2010; 13(3): 243-4[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Iranian Red Crescent Medical Journal accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check